[go: up one dir, main page]

HRP20120421T1 - BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE - Google Patents

BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE Download PDF

Info

Publication number
HRP20120421T1
HRP20120421T1 HRP20120421TT HRP20120421T HRP20120421T1 HR P20120421 T1 HRP20120421 T1 HR P20120421T1 HR P20120421T T HRP20120421T T HR P20120421TT HR P20120421 T HRP20120421 T HR P20120421T HR P20120421 T1 HRP20120421 T1 HR P20120421T1
Authority
HR
Croatia
Prior art keywords
binding protein
ser
seq
asn
igf
Prior art date
Application number
HRP20120421TT
Other languages
Croatian (hr)
Inventor
Olivia@Raeber
Gadi@Gazit@Bornstein
Xiaodong@Yang
Susan@Ann@Cartlidge
David@William@Tonge
Original Assignee
Medimmune@Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune@Limited filed Critical Medimmune@Limited
Publication of HRP20120421T1 publication Critical patent/HRP20120421T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)

Abstract

Potpuno ljudski izolirani specifični vezni protein koji se po mogućnosti vezuje na inzulinu slične čimbenike rasta II IGF II s križnom reaktivnošćuprema inzulinu sličnom čimbeniku rasta I IGF I i neutralizira aktivnost IGF I i IGF II naznačen time da navedeni vezni protein ili vezni fragment proteina obuhvaća komplementarnu određenu regiju teškog lanca CDR s aminokiselinskim slijedom Ser Tyr Asp Ile Asn SEQ ID NO komplementarnu određenu regiju teškog lanca CDR s aminokiselinskim slijedom Trp Met Asn Pro Asn Ser GlyAsn Thr Gly Tyr Ala Gln Lys Phe Gln Gly SEQ ID NO komplementarnu određenu regiju teškog lanca CDR s aminokiselinskim slijedom Asp Pro Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val SEQ ID NO komplementarnu određenu regiju lakog lanca CDR s aminokiselinskim slijedom Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn His Val Ser SEQ ID NO komplementarnu određenu regiju lakog lanca CDR s aminokiselinskim slijedom Asp Asn Asn Lys Arg Pro Ser SEQ ID NO ikomplementarnu određenu regiju lakog lanca CDR s aminokiselinskim slijedom Glu Thr Trp Asp Thr Ser Leu Ser Ala Gly Arg Val SEQ ID NO Patent sadrži još patentnih zahtjevaA fully human isolated specific binding protein that preferably binds to insulin-like growth factor II IGF II with cross-reactivity to insulin-like growth factor I IGF I and neutralizes the activity of IGF I and IGF II characterized in that said binding protein or binding fragment of the protein comprises a complementary specific region of the heavy chain CDR with the amino acid sequence Ser Tyr Asp Ile Asn SEQ ID NO a complementary specific region of the heavy chain CDR with the amino acid sequence Trp Met Asn Pro Asn Ser GlyAsn Thr Gly Tyr Ala Gln Lys Phe Gln Gly SEQ ID NO complementary specific region of heavy chain CDR with amino acid sequence Asp Pro Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val SEQ ID NO complementary specific region of light chain CDR with amino acid sequence Ser Gly Ser Ser Ser Ser Asn Ile Glu Asn Asn His Val Ser SEQ ID NO complementary specific region of light chain CDR with amino acid sequence Asp Asn Asn Lys Arg Pro Ser SEQ ID NO is complementary to a certain region of the light chain CDR with an amino acid sequence Glu Thr Trp Asp Thr Ser Leu Ser Ala Gly Arg Val SEQ ID NO The patent contains additional claims

Claims (18)

1. Potpuno ljudski izolirani specifični vezni protein koji se po mogućnosti vezuje na inzulinu slične čimbenike rasta-II (IGF-II) s križnom reaktivnošću prema inzulinu sličnom čimbeniku rasta I (IGF-I) i neutralizira aktivnost IGF-I i IGF-II, naznačen time da navedeni vezni protein ili vezni fragment proteina obuhvaća: komplementarnu određenu regiju teškog lanca 1 (CDR 1) s aminokiselinskim slijedom "Ser Tyr Asp Ile Asn" (SEQ ID NO: 33); komplementarnu određenu regiju teškog lanca 2 (CDR 2) s aminokiselinskim slijedom "Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly" (SEQ ID NO: 34); komplementarnu određenu regiju teškog lanca 3 (CDR 3) s aminokiselinskim slijedom "Asp Pro Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val" (SEQ ID NO: 35); komplementarnu određenu regiju lakog lanca 1 (CDR 1) s aminokiselinskim slijedom "Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn His Val Ser" (SEQ ID NO: 36); komplementarnu određenu regiju lakog lanca 2 (CDR 2) s aminokiselinskim slijedom "Asp Asn Asn Lys Arg Pro Ser" (SEQ ID NO: 37); i komplementarnu određenu regiju lakog lanca 3 (CDR 3) s aminokiselinskim slijedom "Glu Thr Trp Asp Thr Ser Leu Ser Ala Gly Arg Val" (SEQ ID NO: 38).1. A fully human isolated specific binding protein that preferentially binds to insulin-like growth factor-II (IGF-II) with cross-reactivity to insulin-like growth factor I (IGF-I) and neutralizes the activity of IGF-I and IGF-II, characterized by the fact that said binding protein or binding protein fragment includes: complementary heavy chain specific region 1 (CDR 1) with the amino acid sequence "Ser Tyr Asp Ile Asn" (SEQ ID NO: 33); heavy chain complementary specific region 2 (CDR 2) with the amino acid sequence "Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly" (SEQ ID NO: 34); heavy chain complementary specific region 3 (CDR 3) with the amino acid sequence "Asp Pro Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val" (SEQ ID NO: 35); light chain complementary specific region 1 (CDR 1) with the amino acid sequence "Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn His Val Ser" (SEQ ID NO: 36); complementary light chain specific region 2 (CDR 2) with the amino acid sequence "Asp Asn Asn Lys Arg Pro Ser" (SEQ ID NO: 37); and complementary light chain specific region 3 (CDR 3) with the amino acid sequence "Glu Thr Trp Asp Thr Ser Leu Ser Ala Gly Arg Val" (SEQ ID NO: 38). 2. Specifični vezni protein iz Zahtjeva 1, naznačen time da je navedeni vezni protein monoklonalno antitijelo 7.159.2 (ATCC pristupni broj PTA-7424).2. The specific binding protein of Claim 1, characterized in that said binding protein is monoclonal antibody 7.159.2 (ATCC accession number PTA-7424). 3. Specifični vezni protein iz Zahtjeva 1, naznačen time da navedeni vezni protein obuhvaća polipeptid teškog lanca i ima slijed SEQ ID NO.: 6; ili pri čemu navedeni vezni protein obuhvaća polipeptid lakog lanca i ima slijed SEQ ID NO.: 8.3. Specific binding protein from Claim 1, characterized in that said binding protein comprises a heavy chain polypeptide and has the sequence SEQ ID NO.: 6; or wherein said binding protein comprises a light chain polypeptide and has the sequence of SEQ ID NO.: 8. 4. Specifični vezni protein iz bilo kojeg od Zahtjeva 1 ili 3, naznačen time da navedeni vezni protein obuhvaća polipeptid teškog lanca i ima slijed SEQ ID NO.: 6; i pri čemu navedeni vezni protein obuhvaća polipeptid lakog lanca i ima slijed of SEQ ID NO.: 8.4. A specific binding protein from any one of Claims 1 or 3, characterized in that said binding protein comprises a heavy chain polypeptide and has the sequence of SEQ ID NO.: 6; and wherein said binding protein comprises a light chain polypeptide and has the sequence of SEQ ID NO.: 8. 5. Specifični vezni protein iz bilo kojeg od gore navedenih zahtjeva, naznačen time da je navedeni vezni protein potpuno ljudsko monoklonalno antitijelo; ili vezni fragment potpuno ljudskog monoklonalnog antitijela.5. The specific binding protein of any of the above claims, characterized in that said binding protein is a fully human monoclonal antibody; or binding fragment of a fully human monoclonal antibody. 6. Specifični vezni protein iz Zahtjeva 5, naznačen time da je navedeni vezni fragment odabran iz skupine koja se sastoji od Fab, Fab’ ili F(ab’)2 i Fv.6. Specific binding protein from Claim 5, characterized in that said binding fragment is selected from the group consisting of Fab, Fab' or F(ab')2 and Fv. 7. Specifični vezni protein iz bilo kojeg od Zahtjeva 1 do 6 naznačen time da u mješavini s farmaceutski prihvatljivim nositeljem. 7. The specific binding protein of any one of Claims 1 to 6, characterized in that in admixture with a pharmaceutically acceptable carrier. 8. Molekula nukleinske kiselina naznačena time da kodira specifični vezni protein iz bilo kojeg od Zahtjeva 1 do 6. 8. Nucleic acid molecule encoding the specific binding protein of any one of Claims 1 to 6. 9. Vektor naznačen time da sadrži molekulu nukleinske kiseline iz Zahtjeva 8.9. A vector characterized by the fact that it contains the nucleic acid molecule of Claim 8. 10. Stanica domaćina naznačena time da sadrži vektor iz Zahtjeva 9.10. A host cell comprising the vector of Claim 9. 11. Specifični vezni protein iz bilo kojeg od Zahtjeva 1 do 6, naznačen time da se navedeni vezni protein ne vezuje specifično na proteine IGF-II ili IGF-I kada su navedeni proteini vezani na proteine koji vezuju čimbenike rasta. 11. The specific binding protein of any one of Claims 1 to 6, characterized in that said binding protein does not specifically bind to IGF-II or IGF-I proteins when said proteins are bound to growth factor binding proteins. 12. Metoda za utvrđivanje razine inzulinu sličnog čimbenika rasta-II (IGF-II) i inzulinu sličnog čimbenika rasta I (IGF-I) u uzorku pacijenta naznačena time da obuhvaća: dovođenje uzorka iz pacijenta u kontakt sa specifičnim veznim proteinom iz bilo kojeg od Zahtjeva 1 do 6; i utvrđivanje razine IGF-I i IGF-II u navedenom uzorku. 12. A method for determining the level of insulin-like growth factor-II (IGF-II) and insulin-like growth factor I (IGF-I) in a patient sample characterized by comprising: contacting the patient sample with the specific binding protein of any one of Claims 1 to 6; and determining the level of IGF-I and IGF-II in said sample. 13. Korištenje specifičnog veznog proteina iz bilo kojeg od Zahtjeva 1 do 6 naznačeno time da u pripremi lijeka za liječenje zloćudnog tumora. 13. The use of a specific binding protein from any one of Claims 1 to 6, characterized in that in the preparation of a drug for the treatment of a malignant tumor. 14. Primjena Zahtjeva 13, naznačena time da je navedeni zloćudni tumor odabran iz skupine koja obuhvaća: melanom, rak pluća nemalih stanica, gliom, hepatocelularni karcinom (jetrene stanice), tumor štitnjače, rak želuca, rak prostate, rak dojke, rak jajnika, rak mjehura, rak pluća, glioblastom, rak endometrija, rak bubrega, rak debelog crijeva, rak gušterače i epidermoidni karcinom.14. Application of Claim 13, characterized in that said malignant tumor is selected from the group comprising: melanoma, non-small cell lung cancer, glioma, hepatocellular carcinoma (liver cells), thyroid tumor, stomach cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer and epidermoid carcinoma. 15. Primjena Zahtjeva 13 ili 14, naznačena time da je navedeni lijek namijenjen za primjenu u kombinaciji s drugim anti-neoplastičnim lijekom koji se odabire iz skupine koja obuhvaća antitijelo, kemoterapijski agens i radioaktivni lijek.15. Application of Claim 13 or 14, characterized in that said drug is intended for use in combination with another anti-neoplastic drug selected from the group consisting of an antibody, a chemotherapeutic agent and a radioactive drug. 16. Primjena Zahtjeva 13 ili 14, naznačena time da je navedeni lijek namijenjen za primjenu tijekom ili nakon konvencionalne operacije, presađivanja matičnih stanica koštane srži ili presađivanja perifernih matičnih stanica. 16. Use of Claim 13 or 14, characterized in that said drug is intended for use during or after conventional surgery, bone marrow stem cell transplantation or peripheral stem cell transplantation. 17. Konjugat naznačen time da se sastoji od antitijela iz Zahtjeva 5 ili veznog fragmenta istog i terapijskog agensa. 17. Conjugate characterized in that it consists of an antibody from Claim 5 or a binding fragment thereof and a therapeutic agent. 18. Konjugat iz Zahtjeva 17, naznačen time da je terapijski agens toksin; radioizotop; ili farmaceutski pripravak.18. Conjugate from Claim 17, characterized in that the therapeutic agent is a toxin; radioisotope; or pharmaceutical preparation.
HRP20120421TT 2005-12-13 2006-12-08 BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE HRP20120421T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75008505P 2005-12-13 2005-12-13
US75077205P 2005-12-14 2005-12-14
US77474706P 2006-02-17 2006-02-17
US80818306P 2006-05-24 2006-05-24
PCT/US2006/047059 WO2007070432A2 (en) 2005-12-13 2006-12-08 Binding proteins specific for insulin-like growth factors and uses thereof

Publications (1)

Publication Number Publication Date
HRP20120421T1 true HRP20120421T1 (en) 2012-07-31

Family

ID=38110454

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120421TT HRP20120421T1 (en) 2005-12-13 2006-12-08 BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE

Country Status (25)

Country Link
US (4) US7939637B2 (en)
EP (2) EP1979001B1 (en)
JP (1) JP5302007B2 (en)
KR (1) KR101372690B1 (en)
CN (1) CN105753983A (en)
AR (1) AR058322A1 (en)
AT (1) ATE552853T1 (en)
AU (1) AU2006326649B2 (en)
BR (1) BRPI0619786A2 (en)
CA (1) CA2633956C (en)
CY (1) CY1112876T1 (en)
DK (1) DK1979001T3 (en)
EC (1) ECSP088616A (en)
ES (1) ES2385054T3 (en)
HR (1) HRP20120421T1 (en)
IL (2) IL191718A (en)
MX (1) MX2008007688A (en)
NO (1) NO20082634L (en)
PL (1) PL1979001T3 (en)
PT (1) PT1979001E (en)
RS (1) RS52357B (en)
RU (2) RU2492185C2 (en)
TW (1) TW200801040A (en)
UY (1) UY30002A1 (en)
WO (1) WO2007070432A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2365001A3 (en) * 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2006138729A2 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
CA2641310C (en) * 2006-02-03 2013-08-20 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
RU2498999C2 (en) 2006-07-14 2013-11-20 Ац Иммуне Са Humanised antibody to beta amyloid
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2008152422A2 (en) * 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (en) 2007-06-19 2009-04-28 Boehringer Ingelheim Int ANTI-IGF ANTIBODIES
WO2009006336A1 (en) * 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
DK2238166T3 (en) 2007-10-05 2014-01-27 Ac Immune Sa APPLICATION OF ANTI-AMYLOID BETA ANTIBODY FOR EYE DISEASES
MX2010011955A (en) * 2008-04-29 2011-01-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
EP2296703A4 (en) * 2008-05-09 2012-09-05 Dyax Corp IGF-II / IIE GF-BINDING PROTEIN
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102112494A (en) 2008-06-03 2011-06-29 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
RU2011104348A (en) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION
EP2349329A4 (en) 2008-10-14 2012-10-31 Dyax Corp Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
CZ301597B6 (en) * 2008-11-03 2010-04-28 Univerzita Karlova v Praze, 1. Lékarská fakulta Combination of monoclonal antibodies or Fab fragments thereof for use as a medicament and pharmaceutical composition in which these antibodies or their Fab fragments are comprised
EA201100741A1 (en) 2008-11-10 2012-01-30 Новартис Аг ANTIBODIES TO MODIFIED HUMAN IFR-1 / E PEPTIDES
NZ597692A (en) * 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
AU2010282508B2 (en) 2009-08-13 2015-05-28 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRs
AR078254A1 (en) * 2009-09-01 2011-10-26 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
EP2488658A4 (en) * 2009-10-15 2013-06-19 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX341579B (en) 2010-08-03 2016-08-25 Abbvie Inc * Dual variable domain immunoglobulins and uses thereof.
BR112013004581A2 (en) 2010-08-26 2017-06-27 Abbvie Inc dual variable domain immunoglobulins and their uses
WO2012068148A1 (en) * 2010-11-16 2012-05-24 Medimmune, Llc Regimens for treatments using anti-igf antibodies
MX2013008833A (en) * 2011-02-02 2013-12-06 Amgen Inc Methods and compositons relating to inhibition of igf-1r.
DK3138581T3 (en) 2011-03-17 2019-04-15 Univ Birmingham REDIRECTED IMMUNTERY
WO2012142164A1 (en) * 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
WO2013059206A2 (en) 2011-10-17 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-13 AND / OR IL-17
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
BR112015012414A2 (en) * 2012-11-29 2017-09-12 Bayer Healthcare Llc monoclonal antibodies against activated protein c (apc)
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2014150840A1 (en) * 2013-03-15 2014-09-25 Medimmune, Llc Methods of treating breast cancer
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
BR112015023797A2 (en) 2013-03-15 2017-10-24 Abbvie Inc dual specificity binding proteins directed against il-1b and / or il-17
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP2017502025A (en) * 2013-12-19 2017-01-19 メディミューン，エルエルシー Compositions and methods for treating sarcomas
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
JP6914193B2 (en) 2015-06-24 2021-08-04 Ｊｃｒファーマ株式会社 Fusion protein containing BDNF
TWI833178B (en) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 Novel anti-human transferrin receptor antibodies cross the blood-brain barrier
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
BR112020019559A2 (en) 2018-03-26 2021-01-12 Amgen Inc. TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
KR20210105890A (en) 2018-12-17 2021-08-27 레비토프 리미티드 Twin Immune Cell Engager
AU2020217012A1 (en) * 2019-02-01 2021-08-19 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
KR20220069982A (en) 2019-09-26 2022-05-27 암젠 인크 Methods for producing antibody compositions
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (en) 2020-10-15 2023-05-03 Amgen Inc Relative unpaired glycans in antibody production methods.
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
US20250076309A1 (en) 2021-10-05 2025-03-06 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CN114031685B (en) * 2022-01-10 2022-03-25 中国人民解放军军事科学院军事医学研究院 Fully human anti-new coronavirus neutralizing antibody ZW2G10 and application
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
GB1047304A (en) 1963-07-05
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE12348T1 (en) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
JPS58166634A (en) 1982-03-29 1983-10-01 Toshiba Corp Positive electrode for organic solvent cell
JPS58166633A (en) 1982-03-29 1983-10-01 Toshiba Corp Positive electrode for organic solvent cell
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (en) 1983-09-26 1991-02-15 Ehrenfeld Udo MEDICATION AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES IN THE CELLULAR AND HUMORAL IMMUNE DEFENSE.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPS62170639A (en) 1986-01-22 1987-07-27 株式会社システムメンテナンス Method for mounting ant-proof panel
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DK0486622T3 (en) 1989-08-09 1999-07-19 Rhomed Inc Direct radiolabelling of antibodies and other proteins with technetium or rhenium
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
FR2664073A1 (en) 1990-06-29 1992-01-03 Thomson Csf MEANS FOR MARKING OBJECTS, METHOD FOR PRODUCING THE SAME, AND DEVICE FOR READING.
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
ATE381614T1 (en) 1992-07-24 2008-01-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
UA58494C2 (en) 1995-06-07 2003-08-15 Зенека Лімітед N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical composition, process for preparing thereof and method for endothelin influence counteraction
DK0843961T3 (en) 1995-08-29 2007-05-21 Kirin Brewery Chimeric mouse and method of producing same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ATE211134T1 (en) 1996-03-05 2002-01-15 4-ANILINOQUINAZOLINE DERIVATIVES
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6417330B1 (en) * 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN1431999A (en) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 Indole derivatives with vascular damagine activity
KR20030014425A (en) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 Colchinol derivatives as vascular damaging agents
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
CZ301712B6 (en) * 2001-01-05 2010-06-02 Pfizer Inc. Antibody to IGF-I receptor and pharmaceutical composition containing such antibody
AU2002353017A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Discovery of therapeutic products
DE60329589D1 (en) 2002-04-30 2009-11-19 Kyowa Hakko Kirin Co Ltd ANTIBODIES AGAINST THE HUMAN "INSULIN-LIKE" GROWTH FACTOR
EP2365001A3 (en) * 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1661582A1 (en) * 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
WO2005027970A1 (en) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Drugs for treating cancer
ATE492562T1 (en) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR
JP5149800B2 (en) 2005-08-17 2013-02-20 アメリカ合衆国 Human monoclonal antibody that specifically binds to IGF-II
JP6071725B2 (en) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 Driving force control device for electric vehicles
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
BRPI0619786A2 (en) 2011-10-18
US8410058B2 (en) 2013-04-02
DK1979001T3 (en) 2012-07-16
EP2404616A3 (en) 2012-02-29
RU2008128355A (en) 2010-01-20
CN105753983A (en) 2016-07-13
CA2633956A1 (en) 2007-06-21
HK1124764A1 (en) 2009-07-24
PT1979001E (en) 2012-07-13
WO2007070432A3 (en) 2007-11-29
ES2385054T3 (en) 2012-07-17
ECSP088616A (en) 2008-08-29
MX2008007688A (en) 2008-09-26
ATE552853T1 (en) 2012-04-15
AR058322A1 (en) 2008-01-30
CY1112876T1 (en) 2016-04-13
TW200801040A (en) 2008-01-01
AU2006326649B2 (en) 2011-03-24
IL234798A (en) 2016-02-29
NO20082634L (en) 2008-09-08
US20070196376A1 (en) 2007-08-23
JP5302007B2 (en) 2013-10-02
EP2404616A2 (en) 2012-01-11
RU2013125306A (en) 2014-12-10
US9796779B2 (en) 2017-10-24
EP1979001A2 (en) 2008-10-15
WO2007070432A2 (en) 2007-06-21
US20130274450A1 (en) 2013-10-17
PL1979001T3 (en) 2012-09-28
KR20080089592A (en) 2008-10-07
IL191718A0 (en) 2009-02-11
IL191718A (en) 2014-08-31
RU2549703C2 (en) 2015-04-27
RS52357B (en) 2012-12-31
AU2006326649A1 (en) 2007-06-21
US20160090414A1 (en) 2016-03-31
US20110200607A1 (en) 2011-08-18
RU2492185C2 (en) 2013-09-10
JP2009519711A (en) 2009-05-21
UY30002A1 (en) 2007-07-31
US9181336B2 (en) 2015-11-10
EP1979001B1 (en) 2012-04-11
CA2633956C (en) 2016-12-06
US7939637B2 (en) 2011-05-10
KR101372690B1 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
HRP20120421T1 (en) BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
Tang et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments
CN103288935B (en) Polypeptide
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
Bradley et al. Increased expression of the epidermal growth factor receptor on human colon carcinoma cells
US20110200525A1 (en) Vhh antibody fragments for use in the detection and treatment of cancer
CN101310770A (en) Antibodies against cancer
CN105367657A (en) Anti-HER3 antibody, preparing method thereof and applications of the antibody
CN101553501A (en) IL-21 variants
CN113512117B (en) An antibody capable of binding to CD206 and its application
WO2023241621A1 (en) Anti-liv-1-antibody and antibody-drug conjugate
CN119013305A (en) Monoclonal antibodies targeting GPC3 and antibody drug conjugates comprising such antibodies
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5
US20170114099A1 (en) New polypeptide
Rosik et al. Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging
CN117659203B (en) Anti-MET/EGFR bispecific antibody and drug conjugate thereof
CN110950931A (en) Polypeptide for specifically targeting triple negative breast cancer stem cells and application thereof
CN110627905A (en) Bifunctional fusion protein targeting VEGF and EGFR and its application
WO2004081027B1 (en) Neoplasm specific antibodies and uses thereof
EP4545563A1 (en) Antibodies targeting itga2 and antibody-drug conjugates comprising same
WO2021229104A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
CN113788896A (en) anti-MSLN monoclonal internalization antibody and preparation method and application thereof
Cornelissen et al. In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy
CN106084009A (en) Human osteosarcoma U2 OS cell-specific Binding peptide and application thereof
CN114989270B (en) Polypeptide with binding affinity to humanized CEA and application thereof